» Articles » PMID: 9050124

The Life Course of Schizophrenia: Age and Symptom Dimensions

Overview
Journal Schizophr Res
Specialty Psychiatry
Date 1997 Jan 17
PMID 9050124
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

The life course of schizophrenia has eluded description for several reasons, including fluctuations in diagnostic criteria over the past century, and dramatic changes in treatment and expectations of the mentally ill. This study compared symptoms within a group of patients spanning ages 14 through 73. The three symptom dimensions (psychotic, disorganized and negative) were examined separately in relation to age. Using a multivariate analysis, the effects of age, sex and institutional status were found to have main effects for symptom severity with no interaction effects. The effect of age was significant in the negative direction for positive and disorganized symptoms. Age was specifically associated with decreased hallucinations, delusions, bizarre behavior and inappropriate affect. There was no age effect for formal thought disorder, nor was there an age effect for negative symptoms. Institutionalization was associated with greater symptom severity in all dimensions. Male gender was associated with greater severity of negative symptoms. We conclude that psychotic and disorganized symptoms are likely to be of lesser severity in older patients with schizophrenia, while negative symptoms tend to persist. Clinically, these findings suggest that medications targeting negative symptoms may confer the greatest benefit in treating the older patient with schizophrenia.

Citing Articles

Negative Symptoms and Their Associations With Other Clinical Variables and Working Memory Across the Schizophrenia Spectrum and Bipolar Disorder.

De Pieri M, Berg X, Georgiadis F, Brakowski J, Burrer A, Sabe M Schizophr Bull Open. 2024; 5(1):sgae024.

PMID: 39430551 PMC: 11487101. DOI: 10.1093/schizbullopen/sgae024.


Comparing the latent state-trait structure of the PANSS in cariprazine-medicated and placebo-controlled patients with acute schizophrenia.

Kruckl J, Acsai K, Dombi Z, Moeller J, Lieb R, Lang U Eur Arch Psychiatry Clin Neurosci. 2024; 274(6):1333-1341.

PMID: 38553640 PMC: 11362189. DOI: 10.1007/s00406-024-01790-3.


Estrogen and psychosis - a review and future directions.

Mu E, Gurvich C, Kulkarni J Arch Womens Ment Health. 2024; 27(6):877-885.

PMID: 38221595 PMC: 11579214. DOI: 10.1007/s00737-023-01409-x.


Sex and pubertal influences on the neurodevelopmental underpinnings of schizophrenia: A case for longitudinal research on adolescents.

Barendse M, Lara G, Guyer A, Swartz J, Taylor S, Shirtcliff E Schizophr Res. 2023; 252:231-241.

PMID: 36682313 PMC: 10725041. DOI: 10.1016/j.schres.2022.12.011.


Disentangling age- and disease-related alterations in schizophrenia brain network using structural equation modeling: A graph theoretical study based on minimum spanning tree.

Liu X, Yang H, Becker B, Huang X, Luo C, Meng C Hum Brain Mapp. 2021; 42(10):3023-3041.

PMID: 33960579 PMC: 8193510. DOI: 10.1002/hbm.25403.